5 Contradicted by research
Macular degeneration and glaucoma are the two leading causes of blindness globally.
"Even macular degeneration, glaucoma, the two leading causes of blindness in the world, both of them are really, really easily treated by this uh new mechanism." (said at 0:05:00)
Global epidemiological data show that cataract is by far the single leading cause of blindness worldwide, accounting for roughly 15.2 million cases in people aged 50 and older. According to the Global Burden of Disease Study and Vision Loss Expert Group, glaucoma ranks second (3.6 million cases), undercorrected refractive error ranks third (2.3 million cases), and age-related macular degeneration ranks fourth (1.8 million cases). While glaucoma and macular degeneration are major causes of irreversible blindness (particularly in high-income regions), they are not the two leading causes of blindness globally.
Clinical trials by Samuel Klein administering NMN to humans with obesity or prediabetes showed improvements in lipid profiles, blood pressure, and body weight.
"Samuel Klein, you could look up in PubMed, he's got a couple of really good papers giving NMN, which is the precursor to NAD, to people that are either obese or have pre-diabetes or even super fit ones. Maybe the super fit isn't published yet, but he's done the work and reported about it. You see improvements from lipids, whole bunch of lipids, cholesterol, blood pressure, body weight." (said at 1:00:40)
Samuel Klein and colleagues conducted a 10-week randomized, double-blind, placebo-controlled trial evaluating NMN supplementation in overweight or obese postmenopausal women with prediabetes (PMID 33888596). While the study demonstrated that NMN increased skeletal muscle insulin sensitivity and insulin signaling pathways, it found no significant changes in body weight, blood pressure, plasma lipids (including cholesterol and triglycerides), or body composition between the NMN and placebo groups. The claim that this trial showed improvements in lipids, cholesterol, blood pressure, and body weight is contradicted by the published trial data.
GLP-1 receptor agonists slow motility through the gut, which helps with conditions such as SIBO, Candida, and H. pylori.
"Well, I mean, I know that some of the proposed positive effects for GLP-1s include slowing motility through the gut, which actually helps with things like SIBO or candida or H. pylori because the pace this is why every body every bro lifter that's listening to this you you at some point in your life have glanced off the bottom of SIBO or maybe have it right now" (said at 0:30:36)
The speaker gets the physiological relationship backwards. While GLP-1 receptor agonists do slow gastrointestinal motility and gastric emptying, delayed gut transit and impaired migrating motor complex activity are primary pathophysiological causes and risk factors for small intestinal bacterial overgrowth (SIBO) and fungal overgrowth (Candida), not treatments. Prokinetics that accelerate motility are used therapeutically for SIBO, whereas GLP-1 receptor agonists significantly increase the risk of developing SIBO.
- contradicts: The importance of food quality, gut motility, and microbiome in SIBO development and treat… (Nutrition (Burbank, Los Angeles County, Calif.) 2024) · cited 17x in the literature
"The primary cause of excessive fermentation in the small intestine is a malfunctioning gastrointestinal motor complex, which results in the gut's longer retention of food residues." (abstract, background, passage verified)
pubmedfull study (doi) - contradicts: Small Intestinal Bacterial Overgrowth (SIBO) - Prevention and Therapeutic Role of Nutritio… (Current pharmaceutical design 2025) · cited 5x in the literature
"Furthermore, prokinetics that enhance gastrointestinal motility may offer possible therapeutic advantages in the future." (abstract, conclusions, passage verified)
pubmedfull study (doi) - contradicts: Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgr… (Diagnostics (Basel, Switzerland) 2025) · cited 1x in the literature
"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) effectively manage type 2 diabetes mellitus (T2DM) but may impair gastrointestinal motility, increasing the risk of small intestinal bacterial overgrowth (SIBO)... Short-term analysis demonstrated a higher incidence of diagnostically confirmed SIBO in patients treated with GLP-1 RA/GIP (0.177 per 1000 patient-years) compared to OSLT2DM (0.083 per 1000 patient-years; HR 2.14, 95% CI 1.13-4.07; p = 0.0491)." (abstract, results and background, passage verified)
pubmedfull study (doi)
GLP-1 receptor agonist drugs carry an increased, though low, risk of kidney issues and blindness.
"There is increased risk—low risk—of kidney issues and even blindness. Don't panic. It doesn't happen very often, so it's still really rare, but it's not perfectly safe." (said at 1:40:10)
The speaker bundles two claims regarding rare adverse risks of GLP-1 receptor agonists (GLP-1 RAs):
1. Blindness: Observational studies have identified an association between semaglutide and a modest increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that causes sudden vision loss, consistent with a very low absolute risk (e.g., ~14.5 cases per 100,000 person-years).
2. Kidney issues: This assertion is contradicted by randomized clinical trial evidence. Systematic reviews and network meta-analyses of large cardiovascular and renal outcome trials show that GLP-1 RAs do not increase the risk of acute kidney injury (AKI) compared with placebo, and in fact provide renoprotective benefits (such as reducing progression of albuminuria and composite renal events). While postmarketing warnings exist for rare volume-depletion-related AKI from severe gastrointestinal side effects, the drug class itself does not intrinsically increase kidney risk and is kidney-protective.
- contradicts: Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. (Clinical journal of the American Society of Nephrology : CJASN 2020) · cited 82x in the literature
"In the 18 trials with a total of 2051 AKI events (range: 1-300) among 156,690 patients with type 2 diabetes only, our network meta-analysis showed that SGLT2 inhibitors were associated with a lower risk of AKI compared with placebo (odds ratio, 0.76; 95% confidence interval, 0.66 to 0.88), whereas both DPP-4 inhibitors and GLP-1RAs had neutral effects on risk of AKI." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptid… (PloS one 2022) · cited 9x in the literature
"GLP-1 receptor agonists were most likely ranked best among the three drugs in reducing composite renal events (80%, moderate-quality evidence)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. (JAMA ophthalmology 2025) · cited 103x in the literature
"The incidence rate of NAION was 14.5 per 100 000 person-years among semaglutide users... SCCS analysis of semaglutide exposure showed an increased risk of NAION (meta-analysis IRR, 1.32; 95% CI, 1.14-1.54; P < .001). Results of this study suggest a modest increase in the risk of NAION among individuals with T2D associated with semaglutide use..." (abstract, results and conclusions)
pubmedfull study (doi)
Obesity is the leading cause of malnutrition globally.
"It's like the number one leading cause of malnutrition globally is obesity." (said at 1:42:37)
Obesity is not the cause of malnutrition; rather, international public health authorities (such as the World Health Organization and the Lancet Commission) classify overweight and obesity as a distinct form of malnutrition (overnutrition). Malnutrition encompasses three broad groups of conditions: undernutrition (wasting, stunting, underweight), micronutrient-related malnutrition, and overweight/obesity. Global epidemiological data show that obesity has become the most prevalent form of malnutrition in many countries, driven by dietary changes (such as ultra-processed foods) and physical inactivity, but it is a manifestation of malnutrition rather than its leading cause.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.